An observational study in Hypertension, sponsored by Istituto Auxologico Italiano. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-03.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertension by Istituto Auxologico Italiano — 5 open to participants now, 5 under way, none of them phase 3. Hypertension · Istituto Auxologico Italiano.
Among the 14 studies in Hypertension by Istituto Auxologico Italiano, this one is one of 4 that started in 2022, is one of 7 observational ones, and was the 13th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →5 of the 14 studies in Hypertension by Istituto Auxologico Italiano are open now, in 3 countries. Recruiting first, the newest first:
Istituto Auxologico Italiano · Sites in Italy
Ages 18+
Istituto Auxologico Italiano · Sites in Italy
Ages 75+
Istituto Auxologico Italiano · Sites in Italy
Ages 18+
Istituto Auxologico Italiano · Sites in Argentina, China
Ages 18–80
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 200 across the 7 interventional studies, 220 across the 7 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
2 of the studies in Hypertension by Istituto Auxologico Italiano that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309511Istituto Auxologico ItalianoSubendocardial Viability Ratio in Hypertension | 2026-12-31 |
| NCT06868069Istituto Auxologico ItalianoStudy on Blood Pressure Variability and Frailty in the Older People | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Hypertension by Istituto Auxologico Italiano, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the research is to evaluate the Subendocardial Viability Ratio (SEVR) in hypertensive patients, using non-invasive arterial tonometry, and to establish the influencing factors and the possibility of predicting cardiovascular morbidity and mortality in arterial hypertension.
The SEVR will be evaluated on all patients belonging to the Arterial Hypertension Centers undergoing non-invasive arterial tonometry.
The SEVR is calculated on the morphology of the central pressure wave as the ratio between the DPTI (diastolic pressure-time index), i.e. the area between the carotid pressure curve and the ventricular pressure curve during the diastolic phase, and the SPTI ( systolic pressure-time index), i.e. the area under the carotid pressure curve during the systolic phase.
The SEVR will be correlated with the anthropometric and pathology variables which will be collected in an appropriate database.
Hypertensive patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Arterial transcutaneous tonometry
Buckberg index
Assessment of subendocardial viability ratio (SEVR)
Time frame: At recruitment, at 1 year, 2 years, 3 years and 4 years of follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.
Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 50 months is above that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →